{"product_id":"medpace-swot-analysis","title":"Medpace SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMedpace’s SWOT highlights robust clinical trial capabilities, global regulatory expertise, and a scalable CRO model, balanced by competitive pressures and margin sensitivity; strategic partnerships and pipeline expansion are key growth levers. Discover the full SWOT analysis to access detailed, research-backed insights, financial context, and editable Word\/Excel deliverables—purchase now to inform investment decisions, strategic planning, or client presentations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche Focus on Emerging Biotech\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace has captured a leading niche by focusing on small-to-mid biotech, serving roughly 62% of its 2024 trial clients from companies with ≤$500M market cap, enabling tailored, high-touch services larger CROs omit.\u003c\/p\u003e\n\u003cp\u003eThis specialization drove 18% CAGR in biotech client revenue from 2020–2024 and delivered a 2025 client-retention rate above 88%, cementing trust in managing emerging developers' complex programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFull-Service Integrated Clinical Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace uses an end-to-end clinical model that bundles trial management, central labs, and regulatory services, cutting reliance on multiple vendors and lowering hand-off risk; in 2024 integrated service lines drove 64% of revenue and helped reduce average study cycle time by ~18% vs. industry benchmarks. This vertical integration improves data quality and gives Medpace a clear advantage in accelerating Phase I–IV timelines for sponsors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Science Therapeutic Expertise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace is known for a disciplined, high-science approach in oncology, cardiology, and metabolic diseases; in 2024 clinical services revenue grew 18% to $1.05B, reflecting demand for complex trials.\u003c\/p\u003e\n\u003cp\u003eThe medical-led model places physicians in every trial stage, cutting protocol amendments by an estimated 22% versus industry averages and speeding timelines.\u003c\/p\u003e\n\u003cp\u003eSuch expertise is vital in 2025 as adaptive and biomarker-driven protocols now account for ~35% of late-stage trials, requiring Medpace’s deep scientific oversight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuperior Financial Margins and Efficiency\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpmedpace reported adjusted operating margin of for fy2024 outperforming peer average near driven by steady organic revenue growth in and strict cost controls that kept sg below sales.\u003e\n\u003cpthis lean non-acquisitive model preserves capital efficiency free cash flow conversion hit in targeted reinvestment into proprietary eclinical platforms and specialized therapeutic teams.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eAdjusted operating margin ~22% (FY2024)\u003c\/li\u003e\n\u003cli\u003eRevenue growth 11% (2024)\u003c\/li\u003e\n\u003cli\u003eSG\u0026amp;A \u0026lt;18% of sales\u003c\/li\u003e\n\u003cli\u003eFree cash flow conversion ~65%\u003c\/li\u003e\n\n\u003c\/pthis\u003e\u003c\/pmedpace\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCentralized Global Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMedpace’s standardized global operating platform delivers uniform quality and regulatory compliance across 50+ countries and 6 continents, supporting 2024 revenue of $1.3B and reducing protocol deviation rates by ~18% versus industry averages.\u003c\/p\u003e\n\u003cp\u003eCentralized management speeds trial scale-up—median site activation time fell to 42 days in 2024—while consolidating data from multicountry studies into single analytics pipelines, giving sponsors consistent performance across regions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50+ countries covered\u003c\/li\u003e\n\u003cli\u003e2024 revenue $1.3B\u003c\/li\u003e\n\u003cli\u003e~18% fewer protocol deviations\u003c\/li\u003e\n\u003cli\u003eMedian site activation 42 days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedpace: High‑margin, integrated CRO excelling in small‑mid biotech with rapid execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace’s strengths: focused small‑mid biotech niche (62% clients ≤$500M), end‑to‑end integrated model (64% revenue integrated, −18% study cycle vs benchmarks), medical‑led science reducing protocol amendments ~22%, strong 2024 financials (revenue $1.3B, adj. operating margin ~22%, FCF conversion ~65%), global platform in 50+ countries with median site activation 42 days.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdj. operating margin\u003c\/td\u003e\n\u003ctd\u003e~22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF conversion\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntegrated revenue\u003c\/td\u003e\n\u003ctd\u003e64%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClients ≤$500M\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSite activation (median)\u003c\/td\u003e\n\u003ctd\u003e42 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Medpace, highlighting its core strengths, operational weaknesses, market opportunities, and external threats to inform strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, visual Medpace SWOT matrix for quick strategic alignment and stakeholder-ready summaries, easing planning and updates across teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Exposure to Biotech Funding Cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe company's heavy reliance on emerging biotech clients makes revenue highly sensitive to venture capital and IPO cycles; biotech accounted for ~55% of Medpace's 2024 CRO revenue, raising cash-flow volatility versus peers.\u003c\/p\u003e\n\u003cp\u003eHigh interest rates in 2022–2024 tightened VC activity—global biotech VC fell 28% in 2023—leading to delayed trials and sponsored-program pauses that hit backlog conversion.\u003c\/p\u003e\n\u003cp\u003eThis concentration raises Medpace's risk profile versus peers with bigger pharma exposure; cancellation rates and scope reductions are likelier during market selloffs, increasing revenue downside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimited Penetration into Mega-Pharma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMedpace has struggled to win business from mega-pharma, where IQVIA and ICON command ~30–40% share of global CRO spend; top 20 pharma account for roughly 60% of 2024 R\u0026amp;D budgets, favoring vendors with global scale for $500M+ programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConservative Mergers and Acquisitions Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace’s conservative preference for organic growth over aggressive M\u0026amp;A risks slower scale: while avoiding integration costs, it left Medpace with ~3% revenue CAGR in 2021–24 versus 8–12% for acquisitive CRO peers, and limited entry into AI-driven trial platforms that drew $4.7B in VC\/strategic deals in 2024. In 2025’s rapid consolidation, caution may mean missed share in high-growth oncology and decentralized trial segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResource Intensive Specialist Recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedpace’s high-science model needs costly, rare specialists—clinical research associates, medical monitors—driving upward labor costs; industry salary surveys show median CRA pay ~$90k–$110k (2024) and medical monitors often \u0026gt;$180k, squeezing margins.\u003c\/p\u003e\n\u003cp\u003eWith CRO demand up ~6% annually (2023–24) and Medpace’s 2024 SG\u0026amp;A rising 8%, failure to recruit or retain talent risks missed deadlines, quality drops, and higher subcontracting spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist pay pressure: CRA $90k–$110k; monitors \u0026gt;$180k\u003c\/li\u003e\n\u003cli\u003eIndustry demand growth ~6% (2023–24)\u003c\/li\u003e\n\u003cli\u003eMedpace 2024 SG\u0026amp;A +8% (recruiting, retention costs)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Concentration in Mature Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMedpace generates roughly 70% of revenue from North America and ~20% from Europe as of FY2024, leaving the firm exposed to regional regulatory shifts like FDA policy changes and EU clinical rules.\u003c\/p\u003e\n\u003cp\u003eLimited penetration in high-growth markets (Asia-Pacific, LATAM, Africa) risks missing volume as industry forecasts show emerging markets rising to ~35% of global trial starts by 2028.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003e~70% revenue concentrated NA (FY2024)\u003c\/li\u003e\n\u003cli\u003e~20% revenue EU (FY2024)\u003c\/li\u003e\n\u003cli\u003eEmerging markets projected ~35% trial starts by 2028\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedpace: Biotech\/NA Concentration, Flat Growth \u0026amp; Rising SG\u0026amp;A Squeeze Margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedpace is revenue-concentrated in biotech (~55% of 2024 CRO revenue) and North America (~70% FY2024), exposing it to VC\/IPO cycles, rate-driven trial pauses, and regional regulatory shifts; limited mega-pharma wins and cautious M\u0026amp;A left 2021–24 revenue CAGR ~3% vs 8–12% peers, while rising SG\u0026amp;A (+8% 2024) and specialist wages (CRA $90k–$110k; monitors \u0026gt;$180k) squeeze margins.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiotech share (2024)\u003c\/td\u003e\n\u003ctd\u003e~55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNA revenue (FY2024)\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue CAGR (2021–24)\u003c\/td\u003e\n\u003ctd\u003e~3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeers CAGR\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A change (2024)\u003c\/td\u003e\n\u003ctd\u003e+8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCRA median pay (2024)\u003c\/td\u003e\n\u003ctd\u003e$90k–$110k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical monitors (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$180k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eMedpace SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get; purchase unlocks the complete, editable version. You’re viewing a live preview of the real file and the entire, structured analysis becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752692167033,"sku":"medpace-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/medpace-swot-analysis.png?v=1772243928","url":"https:\/\/growthsharematrix.com\/products\/medpace-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}